Semler Scientific, Inc. SMLR
We take great care to ensure that the data presented and summarized in this overview for Semler Scientific, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMLR
View all-
Interchange Capital Partners, LLC1.28MShares$43.6 Million11.94% of portfolio
-
Morgan Stanley New York, NY737KShares$25 Million0.0% of portfolio
-
Capital International Investors Los Angeles, CA620KShares$21.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA441KShares$15 Million0.0% of portfolio
-
Susquehanna Advisors Group, Inc. Bala Cynwyd, PA408KShares$13.9 Million0.6% of portfolio
-
Black Rock Inc. New York, NY349KShares$11.8 Million0.0% of portfolio
-
Driehaus Capital Management LLC Chicago, IL187KShares$6.35 Million0.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX175KShares$5.94 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$5.8 Million0.0% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA159KShares$5.39 Million0.0% of portfolio
Latest Institutional Activity in SMLR
Top Purchases
Top Sells
About SMLR
Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Insider Transactions at SMLR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Renae Cormier Chief Financial Officer |
BUY
Bona fide gift
|
Indirect |
3,746
+50.0%
|
-
|
|
Jun 11
2025
|
Renae Cormier Chief Financial Officer |
SELL
Bona fide gift
|
Direct |
3,746
-100.0%
|
-
|
|
Jun 11
2025
|
Renae Cormier Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,746
+50.0%
|
$112,380
$30.48 P/Share
|
|
Jun 11
2025
|
Eric Semler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,750
+1.05%
|
$155,250
$23.32 P/Share
|
|
Dec 16
2024
|
Eric Semler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,875
+1.24%
|
$181,125
$23.32 P/Share
|
|
Dec 16
2024
|
William H Chang Director |
SELL
Bona fide gift
|
Indirect |
2,735
-0.62%
|
-
|
|
Dec 12
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
55,000
+26.15%
|
-
|
|
Dec 12
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
55,000
-100.0%
|
-
|
|
Dec 11
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
25,000
-4.48%
|
$1,525,000
$61.68 P/Share
|
|
Dec 11
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,917
+15.72%
|
$44,751
$3.44 P/Share
|
|
Dec 10
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
75,000
-16.42%
|
$4,500,000
$60.96 P/Share
|
|
Dec 10
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
140,083
+50.0%
|
$420,249
$3.44 P/Share
|
|
Nov 07
2024
|
William H Chang Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,318
+27.36%
|
-
|
|
Nov 07
2024
|
Eric Semler Director |
BUY
Open market or private purchase
|
Direct |
50,000
+7.44%
|
$1,850,000
$37.93 P/Share
|
|
Nov 07
2024
|
Eric Semler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,318
+0.23%
|
-
|
|
Nov 07
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
50,000
+33.26%
|
-
|
|
Nov 07
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
50,000
-100.0%
|
-
|
|
Nov 07
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-50.0%
|
$1,850,000
$37.93 P/Share
|
|
Nov 07
2024
|
Douglas Murphy Chutorian Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+35.0%
|
$200,000
$2.7 P/Share
|
|
Nov 07
2024
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,318
+9.96%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.95K shares |
|---|---|
| Bona fide gift | 135K shares |
| Exercise of conversion of derivative security | 344K shares |
| Open market or private purchase | 50K shares |
| Bona fide gift | 138K shares |
|---|---|
| Open market or private sale | 161K shares |